Nanocarry
Michal Roytman Haham is an accomplished biotechnology executive with extensive experience in sales, marketing, and corporate development. Currently serving as Chief Business Officer at Nanocarry Therapeutics since June 2023, Michal previously held several key positions at CollPlant from July 2018 to May 2023, including VP Sales & Marketing, Director Product Sales & Marketing, and Sales & Marketing Manager. Additional experience includes roles at OCON Medical as Product Manager, Neuroderm as Corporate Development Manager, and Galam as Marketing Manager. Early career positions include Sales & Marketing Associate at Neurim Pharmaceuticals Ltd, Scientific/Business Analyst at Frutarom, and Teaching Assistant at Technion - Israel Institute of Technology. Michal holds an MSc and BSc in Biotechnology & Food Engineering from Technion and an MBA in Marketing from Bar-Ilan University.
This person is not in any teams
This person is not in any offices
Nanocarry
Nanocarry is developing a new class of therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases. Using a proprietary “Plug and Play” approach, Nanocarry’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond. Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.